4F

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Retrieved on: 
Sunday, June 5, 2022
Receptor tyrosine kinase, Effector, Survival, DARPA, EIF4A, Breast, Pembrolizumab, RNA transfection, COVID-19, Vomiting, Cancer, U.S. Securities and Exchange Commission, Data analysis, Breast cancer, Software, 4F, CDK, STRI, Nelly, Population, Diarrhea, Patient, EIF4E, KRAS, NSCLC, MD Anderson Cancer Center, Nausea, Anemia, ESR1, University of California, San Francisco, Webcast, Security (finance), MNK, University, PIK3CA, Fulvestrant, Poster, Data, Escape Room, Cyclin E1, Mutation, Private Securities Litigation Reform Act, PK, Research, ER, Fatigue, Cyclin D1, Grade 3, Pfizer, Therapy, GLOBE, NASDAQ, Clinical trial, Protein, Stri Parva, Safety, Pharmaceutical industry, Medical imaging, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today reported positive interim results of the company’s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed treatment was generally well tolerated, resulted in suppression of multiple oncogenic drivers and demonstrated initial signals of clinical activity.

Key Points: 
  • As of the cutoff date of March 4, 2022, interim results showed that zotatifin was generally well tolerated.
  • In the 25 patients who received the recommended Phase 2 dose, none exhibited zotatifin-related Grade 3, 4 or 5 TEAEs.
  • In Part 2 of the trial, early signals of clinical activity were observed in two patients with breast cancer.
  • Coupled with the initial signals of activity, these early results are encouraging for further development of zotatifin, especially in ER+ breast cancer.

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
U.S. Securities and Exchange Commission, Oncogene, RNA transfection, Software, Stri Parva, Annual general meeting, Private Securities Litigation Reform Act, MYC, Cyclic permutation, Infection, Survival, EIF4E, STRI, KRAS, Breast cancer, Webcast, Patient, DARPA, NASDAQ, Therapy, Pharmacokinetics, Clinical trial, Society, Pfizer, COVID-19, American Society of Clinical Oncology, NSCLC, Research, Pembrolizumab, ER, Safety, EIF4A, 4F, ASCO, RNA, Receptor tyrosine kinase, Escape Room, Security (finance), Mutation, Protein, Effector, Cancer, Cyclin D, MNK, GLOBE, Pharmaceutical industry, Vaccine, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it will present interim data from its ongoing Phase 1/2 dose escalation and expansion trial of zotatifin in multiple solid tumors in an oral poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, including safety, pharmacokinetics, pharmacodynamics and responses in two expansion cohorts.

Key Points: 
  • The data to be reported at ASCO represent the first clinical profile for this novel mechanism of action to treat cancer, said Steve Worland, Ph.D., President, and Chief Executive Officer of eFFECTOR.
  • The interim data from our ongoing trial demonstrated that the recommended Phase 2 dose (RP2D) of zotatifin was well-tolerated and achieved pharmacologically active exposures as shown by reductions in target proteins in on-treatment biopsies and by two responses as of the most recent data cut-off in the expansion cohorts.
  • We look forward to sharing more in-depth data and plan to elaborate on our expanded development plans for the zotatifin program during our investor call.
  • eFFECTOR management will host a conference call with commentary from key opinion leaders to provide additional details of the interim study results and discuss upcoming milestones.

eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 10, 2022
D, University, Stri Parva, Research and development, LPC, Cyclic permutation, EDT, MNK, Fulvestrant, NASDAQ, Pembrolizumab, Therapy, Breast cancer, STRI, Patient, Expense, Clinical trial, Program, Research, SAN, ASCO, U.S. Securities and Exchange Commission, Investment, Private Securities Litigation Reform Act, Escape Room, University of California, San Francisco, PD, ER, Security (finance), Survival, EIF4A, D&O, EIF4E, 4F, Effector, R, UCSF, Memory, RNA transfection, Protein, COVID-19, Pfizer, GLOBE, Administration, Cancer, PD-L1, G&A, HIV disease progression rates, KRAS, Pharmaceutical industry, Vaccine, KICKSTART, Income, NSCLC

SAN DIEGO and REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
  • Research and Development (R&D) Expenses: R&D expenses were $3.1 million for the quarter ended March 31, 2022, compared to $4.5 million for the same quarter of 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.4 million for the quarter ended March 31, 2022, compared to $1.3 million for the same quarter of 2021.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, May 2, 2022
Pfizer, EDT, MNK, Stri Parva, NASDAQ, Escape Room, GLOBE, Pembrolizumab, Therapy, ER, STRI, Patient, Survival, EIF4A, Fireside chats, Cancer, EIF4E, 4F, NSCLC, Investor, Conference, RNA transfection, Protein, SAN, KRAS, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

Retrieved on: 
Monday, April 4, 2022
Journal, Therapy, American Medical Association, Effector, Johns Hopkins School of Medicine, NASDAQ, Patient, EIF4E, KRAS, Massachusetts General Hospital, Survival, Biotechnology, Hospital, ER, Cancer, MedImmune, Science, NSCLC, Pfizer, Knowledge, EIF4A, RNA transfection, Stri, GLOBE, MNK, 4F, STRI, SAN, FDA, Protein, Escape Room, JAMA, Pembrolizumab, Amgen, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that its chief medical officer Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer. Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the company’s STRI development programs and will lead clinical development of both tomivosertib and zotatifin. In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022.

Key Points: 
  • Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the companys STRI development programs and will lead clinical development of both tomivosertib and zotatifin.
  • In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022.
  • Before joining Medimmune, he led late-stage clinical development and post marketing efforts for several commercial drugs and drug candidates at Amgen.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 16, 2022
Research, Breast cancer, EIF4A, ER, STRI, PD, G&A, RNA transfection, Pembrolizumab, U.S. Securities and Exchange Commission, PI3K, Cyclic permutation, DARPA, Board of directors, Private Securities Litigation Reform Act, ImmunoGen, Exercise, COVID-19, Administration, Therapy, Clinical trial, Cancer, Population, UCSF, Novartis, D&O, Survival, Research and development, D, MNK, EIF4E, Patient, Memory, Fulvestrant, Escape Room, Pfizer, Senior, LPC, Large-cell lung carcinoma, Security (finance), NASDAQ, Protein, HIV disease progression rates, SAN, Achievement, Effector, GLOBE, Expense, Receptor tyrosine kinase, PD-L1, 4F, Safety, AKT, Chemotherapy, KRAS, Degenerative disease, R, Stri Parva, Pharmaceutical industry, Vaccine, KICKSTART, Income, NSCLC

This cohort will enroll approximately 60 patients, randomized 1:1 to initiate therapy with tomivosertib plus pembrolizumab or placebo plus pembrolizumab.

Key Points: 
  • This cohort will enroll approximately 60 patients, randomized 1:1 to initiate therapy with tomivosertib plus pembrolizumab or placebo plus pembrolizumab.
  • Revenue: Revenue was $0.3 million for the quarter ended December 31, 2021, compared to approximately $42 thousand for the same quarter of 2020.
  • General and Administrative (G&A) Expenses: G&A expenses were $6.3 million for the quarter ended December 31, 2021, compared to $1.1 million for the same quarter of 2020.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

Retrieved on: 
Wednesday, February 16, 2022
Pembrolizumab, NASDAQ, Patient, Cancer, KRAS, Degenerative disease, EIF4A, Stri, MNK, STRI, VP, SAN, RNA transfection, UNC Kenan–Flagler Business School, Chapel Hill, Leadership, GLOBE, Therapy, Escape Room, Gene therapy, Hematology, M.B.A, EIF4E, Protein, Williams College, ER, University of North Carolina at Greensboro, Pfizer, Psychology, Survival, San Francisco, Senior, NSCLC, ImmunoGen, Growth, COVID-19, University, University of California, San Francisco, Novartis, Industry, 4F, Effector, Management, Pharmaceutical industry, KICKSTART

Concurrent with Ms. Harrington-Smiths appointment, Jonathan Root, M.D., has resigned from the companys board of directors.

Key Points: 
  • Concurrent with Ms. Harrington-Smiths appointment, Jonathan Root, M.D., has resigned from the companys board of directors.
  • Kristen is an exceptional strategic thinker with a track record of success launching novel products in oncology, said Steve Worland, President and Chief Executive Officer of eFFECTOR.
  • Dr. Root added, eFFECTOR has made great progress over the years and I am proud to have served on its board since the formation of the company.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, GLOBE, Pembrolizumab, KRAS, EIF4E, Protein, Pfizer, Conference, MNK, STRI, Effector, Company, Cancer, Therapy, Patient, New York Marriott Marquis, EIF4A, 4F, Survival, RNA transfection, ER, BIO, Stri Parva, Escape Room, NSCLC, SAN, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference.
  • Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will provide an overview of the Companys clinical development pipeline and corporate strategy.
  • The presentation will be given in-person at the New York Marriott Marquis on Monday, February 14 at 9:45 am ET.
  • Register to access eFFECTOR Therapeutics presentation, panel and the entire conference on the BIO CEO & Investor Conference event website.

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Retrieved on: 
Monday, January 24, 2022
Survival, ER, Webcast, EIF4E, Patient, Research, STRI, Effector, Private Securities Litigation Reform Act, Clinical trial, SEC, EIF4A, MNK, COVID-19, Pfizer, Population, Safety, Breast cancer, NASDAQ, Protein, CEO, HIV disease progression rates, Pembrolizumab, University of California, San Diego Performance-Based Skills Assessment, GLOBE, ORR, Standard of care, Fulvestrant, U.S. Securities and Exchange Commission, Time, PFS, Therapy, Escape Room, LPC, PD, Form, 4F, Cancer, Pemetrexed, PD-L1, Software, FDA, LLC, Maintenance, Security (finance), Stri Parva, RNA transfection, KRAS, University, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, KICKSTART, NSCLC

SAN DIEGO and REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced multiple pipeline updates for its ongoing development programs, as well as the establishment of an investment agreement with Lincoln Park Capital for a commitment of up to $50 million over 36 months. In the randomized Phase 2b KICKSTART trial of tomivosertib in combination with pembrolizumab in NSCLC, a new cohort has been added to evaluate frontline maintenance in patients with PD-L1 ≥1%, an estimated $5 billion potential U.S. market opportunity. Additionally, the company is discontinuing development of tomivosertib in patients who have already progressed on pembrolizumab monotherapy. Topline data from the ongoing frontline cohort in patients with PD-L1>50% and the new frontline maintenance cohort in patients with PD-L1>1% in the KICKSTART trial are now expected in the first half 2023. Separately, in the Phase 2a trial evaluating zotatifin in patients with solid tumors, the company dosed patients in two new expansion cohorts.

Key Points: 
  • In consideration for entering into the agreement, eFFECTOR issued LPC shares of common stock as a commitment fee.
  • eFFECTOR management will host a conference call to provide additional details and discuss upcoming milestones.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Retrieved on: 
Wednesday, November 24, 2021
Patient, Private Securities Litigation Reform Act, RAS, NSCLC, University of California, San Francisco, Security (finance), Cancer, Cyclin D1, Protein, DARPA, MYC, ER, 4F, Stri Parva, EIF4A, Pfizer, Clinical trial, SEC, SAN, University, RTK, U.S. Securities and Exchange Commission, Frontiers, COVID-19, Receptor tyrosine kinase, Effector, MNK, Escape Room, Pembrolizumab, Survival, Research, GLOBE, STRI, AKT, RNA transfection, EIF4E, PI3K, Therapy, NASDAQ, KRAS, Pharmaceutical industry

The published research showed that zotatifin downregulated the expression of certain receptor tyrosine kinases (RTKs), which are mutated and overexpressed in many cancers.

Key Points: 
  • The published research showed that zotatifin downregulated the expression of certain receptor tyrosine kinases (RTKs), which are mutated and overexpressed in many cancers.
  • These data and other results are informing the selection of biomarker-specific patient populations for the Phase 2a expansion cohorts we initiated earlier this year.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.